CDIX on OTC
Cardiff Lexington Corp
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Basel Medical Group Ltd, HealthLynked Corp or Concord Medical Services Holdings Ltd, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue38¢$4.3M
- Selling, general and admin46¢$5.3M
- Other costs16¢$1.9M
Out of $11.5M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| REVENUE | $11.5M | $8.3M |
| COST OF SALES | $4.3M | $3.8M |
| GROSS PROFIT | $7.2M | $4.4M |
| Depreciation expense | $5.7K | $13.5K |
| Loss on disposal of fixed assets | $12.6K | $0 |
| Share based compensation | $754.5K | $544.7K |
| Selling, general and administrative | $5.3M | $4.1M |
| Total operating expenses | $6.1M | $4.6M |
| INCOME (LOSS) FROM CONTINUING OPERATIONS | $1.1M | -$193.5K |
| Other expense | -$22.1K | -$5.4K |
| Gain on debt refinance and forgiveness | $0 | $78.8K |
| Penalties and fees | -$1.5K | -$1.3K |
| Interest expense | -$6.8M | -$3.0M |
| Amortization of notes payable discount | $0 | -$24.8K |
| Total other expenses | -$6.8M | -$3.0M |
| NET LOSS BEFORE DISCONTINUED OPERATIONS | -$5.7M | -$3.2M |
| INCOME (LOSS) FROM DISCONTINUED OPERATIONS | $238.3K | -$111.3K |
| NET LOSS FOR THE YEAR | -$5.5M | -$3.3M |
| PREFERRED STOCK DIVIDENDS | -$1.0M | -$962.2K |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | -$6.5M | -$4.3M |
| CONTINUING OPERATIONS | -$1 | -$1 |
| DISCONTINUED OPERATIONS | $0 | -$0 |
| CONTINUING OPERATIONS | -$1 | -$1 |
| DISCONTINUED OPERATIONS | $0 | -$0 |
| WEIGHTED AVERAGE SHARES OUTSTANDING BASIC | 6.9M shares | 3.8M shares |
| WEIGHTED AVERAGE SHARES OUTSTANDING DILUTED | 8.5M shares | 3.8M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $318.5K | $1.2M | |
| Accounts receivable, net | $22.1M | $15.9M | $13.3M |
| Prepaid and other current assets | $203.9K | $89.9K | |
| Total current assets | $22.6M | $17.2M | |
| Property and equipment, net | $3.0K | $21.2K | |
| Land | $540.0K | $540.0K | |
| Goodwill | $5.7M | $5.7M | |
| Right of use assets, net | $214.9K | $406.9K | |
| Due from related party | $5.0K | $5.0K | |
| Other assets | $64.2K | $73.4K | |
| Total assets | $29.1M | $23.9M | |
| Accounts payable and accrued expense | $1.8M | $1.4M | |
| Accrued expenses - related parties | $4.6M | $4.6M | |
| Accrued interest | $707.6K | $429.2K | |
| Right of use operating lease liabilities | $178.5K | $223.3K | |
| Notes payable current portion | $125.8K | $312.2K | |
| Notes payable related parties | $1.1M | $0 | |
| Line of credit | $17.2M | $8.6M | |
| Convertible notes payable, net of debt discounts of $131,705 and $0, respectively | $118.3K | $105.0K | |
| Net liabilities of discontinued operations | $0 | $238.3K | |
| Total current liabilities | $25.8M | $15.9M | |
| Notes payable | $138.8K | $251.7K | |
| Operating lease liability long term | $43.0K | $185.9K | |
| Total liabilities | $26.0M | $16.3M | |
| Total Mezzanine Equity | $5.5M | $4.9M | |
| Common Stock; 300,000,000 shares authorized, $0.001 par value; 13,701,698 and 5,100,971 shares issued and outstanding at December 31, 2025 and 2024, respectively | $13.7K | $5.1K | |
| Additional paid-in capital | $72.0M | $22.7M | |
| Unearned stock-based compensation | -$579.2K | $0 | |
| Accumulated deficit | -$79.5M | -$72.9M | |
| Total stockholders' (deficit)/equity | -$2.5M | $2.7M | $731.4K |
| Total liabilities, mezzanine equity and stockholders' (deficit)/equity | $29.1M | $23.9M | |
| Convertible notes payable, debt discount | $131.7K | $0 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares issued | 13.7M shares | 5.1M shares | |
| Common stock, shares outstanding | 13.7M shares | 5.1M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss from operations | -$5.5M | -$3.3M |
| Depreciation | $5.7K | $13.5K |
| Credit losses | $262.9K | $266.0K |
| Change in estimate for settlement realization rate | $0 | $1.7M |
| Amortization of debt discount | $0 | $24.8K |
| Gain on resolution and disposition of discontinued operations claims | -$238.3K | $0 |
| Conversion and note issuance cost | $1.5K | $1.0K |
| Loss on disposal of assets | $12.6K | $0 |
| Interest included in line of credit | $6.4M | $3.1M |
| Share issuance and compensation expense | $754.5K | $544.7K |
| Bonus expense settled with promissory notes | $593.5K | $0 |
| Gain on settlement or forgiveness of debt | $0 | -$78.8K |
| Accounts receivable | -$6.4M | -$4.5M |
| Right of use assets | $275.8K | -$117.9K |
| Prepaids and other current assets | -$104.8K | -$125.0K |
| Accounts payable and accrued expense | $459.8K | -$699.6K |
| Accrued officers compensation | $512.8K | $92.0K |
| Accrued interest | $367.7K | $286.2K |
| Right of use liabilities | -$271.4K | $132.5K |
| Net cash used in operating activities | -$2.9M | -$2.8M |
| Net cash provided by Discontinued Operations Operating | $0 | $111.3K |
| Payments to director | $0 | -$121.0K |
| Proceeds from convertible notes payable | $200.0K | $0 |
| Payments on convertible notes payable | $0 | -$105.1K |
| Repayment on SBA loans | -$8.8K | -$6.7K |
| Payments on note payable | -$300.0K | -$125.0K |
| Net proceeds from line of credit | $2.1M | $3.4M |
| Payment of dividends on preferred stock | -$50.0K | -$100.0K |
| Net cash provided by financing activities | $2.0M | $3.0M |
| NET (DECREASE) INCREASE IN CASH | -$869.6K | $321.2K |
| Cash paid during the year for interest | $9.4K | $126.7K |
| Common stock issued upon conversion of notes payable | $145.9K | $1.7K |
| Common stock issued upon conversion of preferred stock | $8.2K | $5.0K |
| Series Y preferred stock issued in exchange of convertible notes payable | $0 | $3.8M |
| Dividends on preferred stock, including accrued dividends on preferred stock | $1.1M | $1.0M |
| Promissory note payable issued in settlement agreement | $0 | $535.0K |
| Promissory notes payable issued in settlement of bonuses | $1.1M | $0 |
| Discount on convertible notes payable | $131.7K | $0 |
| Unearned compensation on restricted common stock grant | $579.2K | $0 |
Former names
- CARDIFF INTERNATIONAL INCMay 15, 2000 to Jan 26, 20182
Recent filings
- Sep 24, 20268-K
- Sep 15, 20264
- Sep 15, 20264
- Sep 15, 20264
- Sep 4, 20268-K CURRENT REPORT
- Aug 12, 202610-Q FORM 10-Q FOR JUN 2026
- Jun 23, 2026424B3 FORM 424(B)(3)
- Jun 18, 2026EFFECT
- Jun 11, 20268-K
- Jun 11, 2026S-8
- Jun 11, 2026S-1
- May 13, 202610-Q FORM 10-Q FOR MAR 2026
- May 12, 2026AW
- Apr 30, 2026RW
- Apr 3, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11